Table 5.
Results of the bivariable and multivariable cox regression analysis of colorectal cancer patients in TASH, Addis Ababa, Ethiopia
| Variable | Category | Bivariable CHR (95% CI) | Multivariable AHR (95% CI) |
|---|---|---|---|
| Sex | Female | 1 | 1 |
| Male | 1.4 (1.047-1.86)* | 0.89 (0.64-1.24) | |
| Age of patient (yr) | < 40 | 1 | 1 |
| 40-49 | 1.1 (0.71-1.73) | 0.97 (0.60-1.55) | |
| 50-59 | 0.93 (0.62-1.39) | 0.86 (0.50-1.34) | |
| 60-69 | 2.2 (1.46-3.28)*** | 1.5 (0.98-2.40) | |
| ≥ 70 | 2.9 (1.89-4.66)*** | 1.7 (1.02-2.90)* | |
| Residence | Rural | 1 | 1 |
| Urban | 1.3 (0.97-1.77) | 1.3 (0.93-1.80) | |
| Marital status | Single | 1 | 1 |
| Married | 1.4 (0.96-2.105) | 2.4 (1.50-3.80)*** | |
| Widowed | 2.3 (1.31-3.9)** | 2.4 (1.20-4.60)** | |
| Divorced | 2.7 (1.62-4.4)*** | 2.0 (1.1-3.7)* | |
| Smoking status | No | 1 | 1 |
| Yes | 2.4 (1.80-3.19)*** | 1.6 (1.10-2.30)* | |
| Alcohol consumption | No | 1 | 1 |
| Yes | 2.1 (1.59- 2.76)*** | 1.5 (1.07-2.20)* | |
| Comorbidity | No | 1 | 1 |
| Yes | 2.7 (2.10-5.66)*** | 1.8 (1.30-2.50)*** | |
| Stage at diagnosisa | Stage I | 1 | 1 |
| Stage II | 4.8 (1.7-13.9)** | 3.8 (1.3-11.1)* | |
| Stage III | 8.9 (3.2-24.7)*** | 8.0 (2.8-23.3)*** | |
| Stage IV | 18.1 (6.6-50.1)*** | 17.6 (6.1-50.7)*** | |
| Grades of cancer | Differentiated | 1 | 1 |
| Moderately differentiated | 1.6 (1.14-2.4)** | 1.4 (0.94-2.03) | |
| Undifferentiated | 2.8 (2.04-3.89)*** | 1.7 (1.17-2.4)** | |
| Histology type | Adenocarcinoma | 1 | 1 |
| Mucinous carcinoma | 1.4 (0.97-2.02) | 1.2 (0.80-1.75) | |
| Signet-ring-cell carcinoma | 1.8 (1.1-2.9)* | 1.3 (0.71-2.19) | |
| Treatment modality | Radiation alone | 1 | 1 |
| Surgical treatment alone | 0.89 (0.37-2.07) | 0.85 (0.35-2.1) | |
| Chemotherapy alone | 1.8 (0.92-3.5) | 0.82 (0.40-1.7) | |
| Surgery plus chemotherapy | 1.2 (0.61-2.2) | 0.67 (0.34-1.3) | |
| Radiation as neo-adjuvant to surgery | 1.2 (0.58-2.6) | 0.82 (0.37-1.8) | |
| Radiation + surgery + chemotherapy | 1.5 (0.80-2.89) | 0.69 (0.34-1.4) | |
| Didn’t receive treatment | 0.83 (0.10-6.47) | 0.6 (0.07-5.4) |
The total number of 621 subjects were selected from patients registered between January 1, 2013 and December 30, 2017 with follow-up until December 30, 2018. TASH, Tikur Anbessa Specialized Hospital; CHR, crude hazard ratio; AHR, adjusted hazard ratio. aAccording to American Joint Committee of Cancer. *ignificant (P < 0.05), **significant (P < 0.01), ***significant (P < 0.001).